arBtrage CAPITALIZING MARKETS — checking… Sign in Sign up
Calendar /

Immunic, Inc.

IMUX Health Care Biotechnology: Pharmaceutical Preparations
$7.41
▼ -0.9% Today
as of Oct 23, 16:49 ET
Last 30 days -34.02% Sep 14 → Oct 23
$6.29 $7.62 $8.94 $10.27 $11.60 Sep 14 Sep 22 Sep 30 Oct 07 Oct 15 Oct 23
Open
$7.41
High
$7.44
Low
$7.00
Volume
$367,126
Avg Vol
$271,077
Mkt Cap
$118M
P/E (TTM)
—
Beta
—
52w High
$17.43
52w Low
$5.06
Div Yield
—
Shares Out
$14M

Recent Press Releases & News last 60 days · 9 items

Oct 21 · 11:00 PR PR Newswire
Immunic Presents New Clinical, Biomarker, and Preclinical Data for Vidofludimus Calcium in Four Poster Presentations at MSToronto2026 - the 10th Joint ACTRIMS-ECTRIMS Meeting
Oct 19 · 12:27 Proactive
Immunic adds new Chief People Officer ahead of Phase 3 readout
Oct 19 · 10:30 PR PR Newswire
Immunic Appoints Jaa Roberson as Chief People Officer
▸ Show all 9 press releases & news Free account →

IMUX earnings at a glance

The options market is pricing a move of about ±17.3% after the report, a range of roughly $6.13 to $8.69 from today's $7.41. Over its last 2 reports the stock rose the next day 2 times and fell 0, moving ±5.4% on average; after the most recent report on May 13, 2026 it moved +8.8%. That means options currently expect more movement than IMUX has typically delivered. IMUX beat the consensus EPS estimate in 1 of its last 4 reported quarters. Implied volatility is currently 131%. The share price of $7.41 sits near its 52-week low.

More Health Care stocks · All stocks · Earnings calendar

Overview

52-week range
$5.06
$17
19% of range
Avg surprise (last 4)
-8.9%
Avg reaction (last 2)
+5.4%
100% positive
Latest IV / EM
131%
EM ±17.3% · $8 · Oct 16

Earnings trends

EPS — actual vs estimate Actual Estimate
$-1.08$-0.84$-0.60$-0.37$-0.13 Actual $-0.58Actual $-0.54Actual $-0.51Actual $-0.30Actual $-0.21Actual $-0.24Actual $-0.25Est $-0.25Actual $-0.20Est $-0.18Actual $-0.13Est $-0.18Actual $-1.08Est $-0.71Actual $-0.80 MarJunSepMarJunSepMar/2025Jun/2025Sep/2025Mar/2026Jun
Revenue vs Net Income Revenue Net income
$-34M$-32M$-30M$-28M$-26M Sep 24Mar 25Jun 25Sep 25Mar 26Jun 26

Earnings history

DatePeriodActual EPSEstSurpriseYoY %ΔDay reactSource
Tue Jun 30, 2026Jun 2026 $-0.80 — — — — financials
Wed May 13, 2026Mar/2026 $-1.08 $-0.71 -52.1% -332.0% +8.8% earnings
Thu Nov 13, 2025Sep/2025 $-0.13 $-0.18 +27.8% — — earnings
Thu Aug 7, 2025Jun/2025 $-0.20 $-0.18 -11.1% — — earnings
Thu May 15, 2025Mar/2025 $-0.25 $-0.25 0.0% — +1.9% earnings
Mon Sep 30, 2024Sep 2024 $-0.24 — — — — financials
Sun Jun 30, 2024Jun 2024 $-0.21 — — — — financials
Sun Mar 31, 2024Mar 2024 $-0.30 — — — — financials
Sat Sep 30, 2023Sep 2023 $-0.51 — — — — financials
Fri Jun 30, 2023Jun 2023 $-0.54 — — — — financials
Fri Mar 31, 2023Mar 2023 $-0.58 — — — — financials

Financials

Income statement (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue————————
Cost of revenue————————
Gross profit————————
Operating income$-35M$-33M—$-26M$-27M$-27M—$-26M
Net income$-34M$-33M—$-26M$-27M$-25M—$-24M
EPS (diluted)$-0.80$-1.08—$-0.13$-2.03$-2.51—$-0.24

Balance sheet (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Cash & equivalents$155M$187M$15M$35M$55M$14M$36M$59M
Inventory————————
Total current assets$158M$189M$23M$39M$60M$19M$39M$63M
Total assets$159M$190M$24M$41M$61M$21M$41M$65M
Long-term debt————————
Total liabilities$32M$39M$31M$30M$28M$26M$22M$24M
Total equity$128M$151M$-7M$10M$34M$-5M$18M$41M

Implied volatility — last 90 days

29%221%412%604%796% Jun 07 — IV 141% · EM ±19.6%Jun 08 — IV 144% · EM ±19.1%Jun 09 — IV 146% · EM ±18.4%Jun 10 — IV 172% · EM ±20.3%Jun 11 — IV 125% · EM ±13.8%Jun 12 — IV 360% · EM ±36.8%Jun 15 — IV 291% · EM ±21.1%Jun 16 — IV 333% · EM ±19.7%Jun 19 — IV 141% · EM ±31.2%Jun 22 — IV 131% · EM ±27.3%Jun 23 — IV 165% · EM ±33.8%Jun 24 — IV 160% · EM ±32.0%Jun 25 — IV 133% · EM ±26.0%Jun 26 — IV 178% · EM ±34.0%Jun 29 — IV 137% · EM ±24.3%Jun 30 — IV 134% · EM ±23.1%Jul 01 — IV 127% · EM ±21.3%Jul 02 — IV 140% · EM ±22.6%Jul 03 — IV 145% · EM ±22.6%Jul 06 — IV 125% · EM ±17.3%Jul 07 — IV 143% · EM ±18.9%Jul 08 — IV 98% · EM ±12.3%Jul 09 — IV 196% · EM ±23.2%Jul 10 — IV 165% · EM ±18.3%Jul 13 — IV 174% · EM ±14.5%Jul 14 — IV 122% · EM ±8.8%Jul 15 — IV 359% · EM ±21.2%Jul 16 — IV 797% · EM ±33.3%Jul 20 — IV 113% · EM ±26.7%Jul 21 — IV 144% · EM ±33.5%Jul 22 — IV 160% · EM ±36.6%Jul 23 — IV 148% · EM ±33.3%Jul 24 — IV 151% · EM ±33.4%Jul 27 — IV 167% · EM ±34.9%Jul 28 — IV 123% · EM ±25.1%Jul 29 — IV 234% · EM ±46.9%Jul 30 — IV 163% · EM ±31.9%Jul 31 — IV 146% · EM ±27.9%Aug 03 — IV 149% · EM ±26.4%Aug 04 — IV 135% · EM ±23.3%Aug 05 — IV 130% · EM ±21.8%Aug 06 — IV 123% · EM ±19.9%Aug 07 — IV 143% · EM ±22.4%Aug 10 — IV 148% · EM ±20.6%Aug 11 — IV 103% · EM ±13.6%Aug 12 — IV 200% · EM ±25.1%Aug 13 — IV 291% · EM ±34.3%Aug 14 — IV 294% · EM ±32.4%Aug 17 — IV 228% · EM ±19.0%Aug 18 — IV 405% · EM ±29.3%Aug 19 — IV 196% · EM ±11.6%Aug 20 — IV 394% · EM ±16.5%Aug 24 — IV 89% · EM ±18.5%Aug 25 — IV 102% · EM ±20.9%Aug 26 — IV 149% · EM ±29.9%Aug 27 — IV 135% · EM ±26.4%Aug 28 — IV 70% · EM ±13.5%Aug 31 — IV 100% · EM ±17.7%Sep 01 — IV 97% · EM ±16.6%Sep 02 — IV 105% · EM ±17.6%Sep 03 — IV 142% · EM ±22.9%Sep 04 — IV 46% · EM ±7.2%Sep 07 — IV 52% · EM ±7.2%Sep 08 — IV 108% · EM ±14.3%Sep 09 — IV 85% · EM ±10.7%Sep 10 — IV 122% · EM ±14.4%Sep 11 — IV 230% · EM ±25.4%Sep 14 — IV 533% · EM ±44.5%Sep 15 — IV 627% · EM ±45.3%Sep 21 — IV 85% · EM ±17.8%Sep 22 — IV 29% · EM ±6.0%Sep 23 — IV 115% · EM ±22.9%Sep 24 — IV 101% · EM ±19.9%Sep 25 — IV 129% · EM ±24.6%Sep 28 — IV 125% · EM ±22.1%Sep 29 — IV 125% · EM ±21.6%Sep 30 — IV 164% · EM ±27.4%Oct 01 — IV 200% · EM ±32.4%Oct 02 — IV 165% · EM ±25.8%Oct 06 — IV 131% · EM ±17.3%

Sector peers

AARD
Aardvark Therapeutics, Inc.
$115M $1.39-68.5%
LIXT
Lixte Biotechnology Holdings, Inc.
$115M $7.21+75.8%
GNLX
Genelux Corporation
$114M $2.00-3.4%
CRBP
Corbus Pharmaceuticals Holdings, Inc.
$123M $4.05-5.5%
PYPD
PolyPid Ltd.
$109M $5.25+3.5%
SPRB
Spruce Biosciences, Inc.
$129M $45.15+5.7%

IMUX earnings FAQ

What is IMUX's expected move for earnings?

Options currently price a move of about ±17.3%, or $1.28 per share either way from $7.41.

How does IMUX stock usually react to earnings?

Across the last 2 reports the average next-day move was ±5.4%, up 2 times and down 0 times.

What is IMUX's implied volatility?

IMUX's at-the-money implied volatility is about 131% based on the latest options snapshot.

View on Nasdaq ↗
🔒 Preview mode. Create a free account to unlock the full earnings calendar, all panels, heatmaps, options flow, and screener.
Sign up free → Sign in